TAMPA, Fla.--(BUSINESS WIRE)--May 15, 2006--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI - News) has released its financial results for the second quarter ended March 31, 2006. The Company’s efforts during the period focused primarily on the development of two potential blockbuster products, SinuNase, an intranasal Amphotericin B formulation for Chronic Sinusitis (CS), and, through its majority-owned subsidiary Biovest International, Inc. (OTCBB:BVTI - News), BiovaxID, a personalized biologic therapeutic vaccine for follicular non-Hodgkin’s lymphoma. Accentia has two business segments: specialty pharmaceuticals, and biopharmaceutical products and services. Biovest, the majority-owned subsidiary, is consolidated with Accentia for reporting purposes.
